The company offers 5,000+ diagnostic tests and panels, including specialised and genomic testing across key laboratory disciplines . Its portfolio includes Genevolve (genomics), L-CoRD (reproductive diagnostics) and L-ACE (autoimmune disorders), along with AI-enabled diagnostics .

Dr. Lal PathLabs has a Pan-India presence with 298 labs, 6,607 patient service centres and 12,365 pick-up points, and also operates in Nepal and Bangladesh through subsidiaries and labs . International operations currently account for less than 2% of revenue .

In FY25, revenue contribution was 74% from B2C and 26% from B2B . International revenue was less than 2%, with the rest from India .